Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
- 1 August 2002
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (12) , 1653-1660
- https://doi.org/10.1016/s0959-8049(02)00107-7
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- ZD0473 phase II monotherapy trial in second-line ovarian cancerEuropean Journal Of Cancer, 2001
- Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell linesEuropean Journal Of Cancer, 2000
- Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum[II])Lung Cancer, 2000
- Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistanceJournal of Inorganic Biochemistry, 1999
- Chemotherapy for ovarian cancer - a consensus statement on standard practiceBritish Journal of Cancer, 1998
- In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473British Journal of Cancer, 1998
- In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell linesCancer Chemotherapy and Pharmacology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell Lines in vitroEuropean Journal Of Cancer, 1995
- Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitroBritish Journal of Cancer, 1994